-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎WuXi AppTec Content Team Editor
Today, the US FDA announced that it has approved the marketing of Provention Bio's drug Tzield (teplizumab).
Used to delay the course
of the disease in specific high-risk groups of type 1 diabetes.
The US FDA press release pointed out that this is also the first drug
that can delay the onset of type 1 diabetes.
Type 1 diabetes is a chronic disease
.
Due to damage to the patient's pancreatic β cells, the amount of insulin they secrete in their bodies is very small, even almost zero! Insulin is an important hormone in the body, and insufficient secretion can lead to abnormal increases in blood sugar levels and abnormal glucose metabolism, inducing a series of metabolic problems
.
A variety of factors can contribute to the development
of type 1 diabetes.
Although the scientific community has done a lot of research on this disease, we still do not have a complete cure
for the disease.
Intervention before pancreatic islet β cells are completely damaged is of great significance
for preserving β cell function and alleviating disease progression.
▲2022 has come to an end
.
In order to have a more comprehensive understanding of the views and insights of friends in the biomedical industry on the development of the industry, we invite you to spend 1 minute in your busy schedule to fill out this questionnaire (long press to scan the code, or
Today, the US FDA announced that it has approved the marketing of Provention Bio's drug Tzield (teplizumab).
Used to delay the course
of the disease in specific high-risk groups of type 1 diabetes.
The US FDA press release pointed out that this is also the first drug
that can delay the onset of type 1 diabetes.
Type 1 diabetes is a chronic disease
.
Due to damage to the patient's pancreatic β cells, the amount of insulin they secrete in their bodies is very small, even almost zero! Insulin is an important hormone in the body, and insufficient secretion can lead to abnormal increases in blood sugar levels and abnormal glucose metabolism, inducing a series of metabolic problems
.
A variety of factors can contribute to the development
of type 1 diabetes.
Although the scientific community has done a lot of research on this disease, we still do not have a complete cure
for the disease.
Intervention before pancreatic islet β cells are completely damaged is of great significance
for preserving β cell function and alleviating disease progression.
▲2022 has come to an end
.
In order to have a more comprehensive understanding of the views and insights of friends in the biomedical industry on the development of the industry, we invite you to spend 1 minute in your busy schedule to fill out this questionnaire (long press to scan the code, or
